Patrick G. Morris
YOU?
Author Swipe
View article: Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies
Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies Open
Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs h…
View article: Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland Open
Background The landscape of perioperative immune checkpoint inhibitor (ICI) therapy for stage III melanoma is rapidly evolving. We conducted a modified Delphi consensus process to the define at an institutional level the optimal approach t…
View article: Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicity
Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: a retrospective institutional review of clinical outcomes and hematological toxicity Open
In conclusion, in patients aged ≥ 70 years compared to those aged < 70 years, we confirm that neoadjuvant chemoradiation is tolerable. There was no evidence to suggest any differences in OS and DFS between the cohorts. Neoadjuvant therapy …
View article: Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer Open
Purpose: Adjuvant trastuzumab therapy has improved outcomes in HER2-positive breast cancer, but the impact of the timing of its initiation remains unclear. This study evaluates the effect of time to adjuvant trastuzumab-based therapy (TTAT…
View article: CTRIAL-IE (ICORG) 15–34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland
CTRIAL-IE (ICORG) 15–34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland Open
Background The 21-gene Breast Recurrence Score® (Oncotype DX®) assay has improved the selection of patients for chemotherapy in early breast cancer. Internationally, this test is used in lymph node positive disease, but at the time this st…
View article: 133 Neoadjuvant HER2 inhibition induces <i>ESR1</i> DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancer
133 Neoadjuvant HER2 inhibition induces <i>ESR1</i> DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancer Open
Background Divergent estrogen receptor (ER) and HER2 status with breast cancer disease progression has important consequences for clinical management and long-term survival. Molecular subtype expression is dynamic and influenced by therape…
View article: Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer Open
Responses to neoadjuvant chemoradiotherapy for locally advanced rectal cancer are not uniform. The phosphatidylinositol-3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways are involved in tumorigenesis and treatment resist…
View article: Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer Open
Purpose The treatment landscape of Oestrogen receptor-positive (ER-positive) breast cancer is evolving, with declining chemotherapy use as a result of Oncotype DX Breast Recurrence Score® testing. Results from the SWOG S1007 RxPONDER trial…
View article: Impact of catastrophic brain injury guidelines on organ donation rates: Results of an EAST multicenter trial
Impact of catastrophic brain injury guidelines on organ donation rates: Results of an EAST multicenter trial Open
BACKGROUND One third of organ donors suffer catastrophic brain injury (CBI). There are no standard guidelines for the management of traumatic CBI prior to brain death, and not all trauma centers have institutional CBI guidelines. In additi…
View article: Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: A retrospective institutional review of clinical outcomes and hematological toxicity
Neoadjuvant chemoradiation in older Irish adult patients with oesophageal cancer: A retrospective institutional review of clinical outcomes and hematological toxicity Open
Background and Objectives: Neoadjuvant chemo-radiotherapy improves survival compared with surgery alone in locally advanced oesophageal cancer. In the Chemo-Radiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) randomised c…
View article: RET overexpression leads to increased brain metastatic competency in luminal breast cancer
RET overexpression leads to increased brain metastatic competency in luminal breast cancer Open
Background Breast cancer brain metastasis is a rising occurrence, necessitating a better understanding of the mechanisms involved for effective management. Breast cancer brain metastases diverge notably from the primary tumor, with gains i…
View article: Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study) Open
Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have signific…
View article: Magnetically Functionalized Hydrogels for High‐Throughput Genomic Applications
Magnetically Functionalized Hydrogels for High‐Throughput Genomic Applications Open
Single‐cell genomics has revolutionized tissue analysis by revealing the genetic program of individual cells. The key aspect of the technology is the use of barcoded beads to unambiguously tag sequences originating from a single cell. The …
View article: Supplementary Figure 2 from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
Supplementary Figure 2 from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women Open
PDF file - 98K
View article: Supplementary Tables 1 - 3 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
Supplementary Tables 1 - 3 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer Open
PDF file - 76K, Additional Patient Characteristics.
View article: Data from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
Data from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women Open
Obesity is a risk factor for hormone receptor-positive breast cancer in postmenopausal women. Estrogen synthesis is catalyzed by aromatase, which is encoded by CYP19. We previously showed that aromatase expression and activity are increase…
View article: Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer Open
Supplementary Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
View article: Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Supplementary Table 1 from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Open
Clinicopathologic features stratified by treatment arm (RNA-seq analysis population).
View article: Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
Data from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer Open
Elevated levels of COX-derived prostaglandin E2 (PGE2) occur in inflamed tissues. To evaluate the potential links between inflammation and breast cancer, levels of urinary prostaglandin E metabolite (PGE-M), a stable end metabolite of PGE2…
View article: Supplementary Figure 1 from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women
Supplementary Figure 1 from Increased Levels of COX-2 and Prostaglandin E<sub>2</sub> Contribute to Elevated Aromatase Expression in Inflamed Breast Tissue of Obese Women Open
PDF file - 41K
View article: Supplementary Appendix 1 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
Supplementary Appendix 1 from Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer Open
PDF file - 30K, Study questionnaire used to collect smoking and NSAID data.
View article: Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease
Data from A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Open
Obesity, a cause of subclinical inflammation, is a risk factor for the development of postmenopausal breast cancer and is associated with poorer cancer outcomes. Docosahexaenoic acid (DHA), an omega-3 fatty acid, possesses anti-inflammator…